

Thyroid metastases from renal cell carcinoma.

Report of a case and review of the literature Digital Edition e-publish on-line ISSN 2239-253X

Direttore Nicola Picardi



Ann Ital Chir, Digital Edition 2018, 7 pii: S2239253X16027791 - Epub, February 26 *free reading*: www.annitalchir.com

Giuseppa Graceffa, Salvatore Vieni, Maria Vittoria Barbagallo, Gabriella Ferrara, Calogero Cipolla, Mario Adelfio Latteri

Department of Surgical Oncological and Oral Sciences, Division of General and Oncological Surgery, University of Palermo, Palermo, Italy

Thyroid metastases from renal cell carcinoma. Report of a case and review of the literature.

Metastases to thyroid gland are a rare occurrence in surgical practice. The most frequent primitive tumor is renal cell carcinoma. We report a case of thyroid metastasis from renal cell carcinoma in a 70-year-old man who underwent left nephrectomy ten years earlier, presented with a diagnosis of multinodular goiter, associated with thyroiditis and right laterocervical lymphadenopathy. A total and the surgical excision of laterocervical lymph node were performed. The results, according to the histological examination, were metastases from renal cell carcinoma, involving both the thyroid gland and the lymph node. Therefore, since the delay of presentation and the difficulties of diagnosis, we recommend log-term follow-up of the head and neck region, for those patients with renal cell carcinoma diagnosis.

Metastases to the thyroid gland are a rare occurrence in surgical practice. This might sound a little surprising, since the rich vascularization of the gland itself. The rarity of metastases in this organ is attributed to the fast blood flow and the high level of oxygen and iodine that could prevent the secondary localization of tumour cells¹. Thyroid metastases represent approximately 1 to 2,4% of all the malignant nodules ², while in autopsies series, the incidence overall rises up to 24% ³⁻⁴, suggesting that the condition is frequently undiagnosed. The most common primary site (48.1%) is renal cell carcinoma (RCC)⁵⁻⁶, with a delay of presentation that could last

until 20 years after the nephrectomy⁷. These secondary localizations have not typical symptoms and ultrasonography (US) and computed tomography (CT) findings do not differ from primitive thyroid tumours, making an early diagnosis almost impossible. Even cytological examination by fine needle aspiration biopsy (FNAB) seems to have uncertain results⁸. In this scenario, thyroidectomy might be a valid option in order to improve outcome and increase survival of patient affected by RCC metastases.

We present a case of a patient with thyroid metastasis from RCC, unexpectedly diagnosed after thyroidectomy for multinodular goitre with suspicion of malignancy.

Case Report

A 70-year-old white man, with personal history of hypertension, splenectomy and RCC for which he underwent left nephrectomy ten years earlier, was referred to our surgical division for a mass in the anterior region of the neck he had previously noticed. At clinical examination, the neck of the patient presented a swelling in the anterior region, and the thyroid resulted hard at the palpation; the inferior margins were impossible to determine,

Pervenuto in Redazione Settembre 2017. Accettato per la pubblicazione Gennaio 2018

Correspondence to: Prof. Calogero Cipolla, Dipartimento di Discipline Chirurgiche Oncologiche e Stomatologiche, Università degli Studi di Palermo, Divisione di Chirurgia Generale ed Oncologica, AOUP Paolo Giaccone, Via del Vespro 129, 90127 Palermo (e-mail: calogero.cipolla@unipa.it)




Fig. 1: A): ultrasonographic features of the left lobe nodule;B)ultrasonographic features of lymph node metastasis.

and multiple nodes were appreciated, bilaterally. An US was performed, which showed thyroid gland globally enlarged, with prevalence of the left lobe. Right lobe was normoechoic, but inhomogeneous for the presence of several hypoechoic spots with undefined margins. Left lobe was hypoechoic, and largely occupied by a nodule of 42 x 33 mm approximately, with rich perinodular vascularization. The US mentioned as well a hypoechoic, homogeneous, solid, well-defined nodule, localized in the third level, poorly vascularized, suspicious for lymph node (Fig. 1). He took blood measurements of thyroid hormones; TSH was 9,49 mlU/L, while fT4, PTH, calcitonin resulted to be in the range of normality. Moreover, the patient underwent FNAB of both thyroid nodule and lateral cervical one, and while the cytological exam of the laterocevical mass showed "epithelial cells", the one of the nodule in the left lobe showed "lymphocytic cells", that rose the suspicion of Hashimoto's thyroiditis. At CT scan, thyroid appeared enlarged with prevalence of the left lobe, and mediastinal invasion with compression and deviation the trachea. Were reported as well few suspicious lateral cervical lymph nodes with inhomogeneous density. An abdominal US was performed as well, and the results were in the range of normality, except for the absence of the spleen and the left kidney; the right kidney resulted to be slightly hypertrophic and hypoechoic.

After completing the preoperative workup, a total thyroidectomy and the surgical excision of the right laterocervical lymphnode were simultaneously performed. During the surgery, thyroid resulted to be of hard-fibrous consistency, especially to the left side where the tissue appeared to be ligneous, and not separable from trachea and oesophagus. The total absence of cleavage plans made the nodule impossible to excise, and a notable gland residue was left in situ.

The histological exam of the gland showed a thyroid weighs 50 grams, with left lobe of cm $5.5 \times 3.2 \times 2.7$, right lobe of cm $5 \times 3.5 \times 2.5$, isthmus of cm $4 \times 1.5 \times 1$, made by compact yellow tissue with multiple subcentimetrical nodes, and four fragment of tissue that appeared white when cut. Thyroid gland resulted to be almost entirely occupied by multiple nodes, merging into each

others, of epithelial clear cells proliferation (Pan-CK+, Vimentin +, CD10+, Rcc+ Thyroglobulin-, HBME-1-). This result seemed to be compatible with renal clear cell carcinoma metastasis (Fig. 2). Moreover, six lymph nodes were found in the fragment of tissue, three of which resulted occupied by the same specimen of tissue of the gland. The post-operative period resulted to be slightly abnormal for hypocalcaemia. During third post-operative day calcium values resulted to be 7.7 mg/dL, for which endovenous substitutive therapy was started. The patient was discharged on seventh post-operative day, with calcium values of 8.52 mg/dL.

Discussion

Thyroid gland has a low frequency of clinical metastatic carcinoma, despite the rich vascularization of the gland. It seems to be related to the high oxygen and iodine concentration, to the highly rapid bloodstream of the thyroid, and to the filtering effect of lungs passage^{1, 9, 10}. When this microenvironment results to be altered by situations such as goitre or thyroiditis, as it happened in our clinical case, the gland becomes a vulnerable territory for metastatic growths. Heffes et al., in the largest series of thyroid metastases from RCC, found pre-existing thyroid disease in 42% of the 36 cases¹¹⁻¹³.

Thyroid metastases represent approximately 1-2,4% of all the malignant nodules²; in autopsies series, the incidence overall is approximately from 1,9% to 24%3-4, and the most common primary site of the tumour are the lungs. In clinical series, instead, the higher frequency of primitive malignancy is attributed to RCC⁶. In general, the most common non-thyroid malignancies metastasizing to the thyroid are RCC (48.1%), colorectal (10.4%), lung (8.3%), breast carcinoma (7.8%), and sarcoma (4.0%)⁵. There are no significative differences in the pattern of thyroid metastases, according to gender or side of the primary kidney tumour, as RCC has a high metastatic potential due to its hematogen and vascular features¹⁴, invading the renal vein, and subsequently the inferior vena cava, the systemic arterial system and finally the thyroid arteries, gaining access the thyroid gland¹⁵.




Fig. 2: Histological and Immunoistochemical characteristic of thyroid metastases from RCC.

Thyroid metastases usually present as a solitary nodule^{5, 16, 17}, and are more frequently a late finding, developing with a latency up to 20 years as a metachronous tumor^{18,19}, even thought 25% of are synchronous to the primitive disease^{9, 14, 20}.

Usually, thyroid metastases have not typical signs and symptoms, and do not differ from other primitive thyroid diseases, as they often present with neck swelling, dysphagia, dysphonia, and respiratory distress¹⁷, while change in functioning are usually late and uncommon⁶. Usually metastases appear in glands in which thyroid tissue is damaged as a result of goitre, primary tumour, or thyroiditis, owing to its decreased oxygen and iodine content^{5,11,21}; few authors have even reported episodes of thyroiditis after chemotherapy²². They could also be asymptomatic^{20,23}, and incidentally diagnosed during imaging, but more frequently the patient complain a fast growing neck mass^{24,25}, as it happened in our clinical case, in which, after ten years of latency, the patient developed a thyroid metastasis that grew in few months.

Diagnosis of thyroid metastases is a challenge, since they have non-specific imaging features and FNAB often provides uncertain cytological results. Metastatic disease in the thyroid gland tends to form a mass that mimics primary tumour, or even benign masses, with few or no suspicious US features²⁶, such as solid nodules, nonhomogeneous, hypoechoic, with noncircumscribed margins, absence of calcifications, and increased vascularity^{3,5,19,28}. Even more sophisticated techniques, such as CT scans and MRI, cannot reliably differentiate between primitive lesions and metastases ²⁸. Radioscintigraphic imaging, using iodine-131 or technetium-99m, results inconclusive as well, since both primary and secondary lesions appear as cold nodule, unable to capture the radioisotopes ^{15, 29}.

FNAB has been considered an important diagnostic tool, with high sensibility and specificity ^{8,30-32}; recently, though, FNAB resulted to be more frequently inaccurate, espe-

cially with RCC metastases ^{8,26,33-38}, and the majority of nondiagnostic FNAB were reported to be benign or indeterminate ^{26,33,35-38}. The diagnostic inaccuracy of FNAB for metastatic thyroid lesions has been associated to several factors; first of all, the hypervascularization of the nodules, since it is associated with higher possibility of blood contamination, that makes cytological examination harder to perform ^{19,38,39}.

Additionally, in order to diagnose RCC metastases, immunohistochemical staining is necessary, and it cannot be performed on FNA specimens, on which only cytological exam is possible^{5,26,38}. Studies with immunohistochemical (IHC) markers such as PAX2, RCC marker, CD10, vimentin, alpha-metylacyl-CoA racemase ⁴⁰ are important in the diagnostic process of this disease, and FNAB does not provide adequate tissue samples ³⁵. Moreover, it does not provide information on primitive disease and it cannot distinguish from high-grade malignancy and anaplastic carcinoma ³⁴. More invasive techniques such as CNB or open biopsies have been proposed, and they have been proven to diagnose metastatic RCC without further investigation ^{12,34,38,41}.

Histopathological analysis is, in fact, superior diagnostic performance compared to cytological one ⁴², and histologically RCC is characterized by high content of lipid material and glycogen (PAS positive) ^{10,15,29,44}, as well as the absence of mucin. This is, though, a nonspecific finding ⁴⁵.

IHC provides important information in RCC metastases diagnosis. Usually, metastases result to be negative for thyroglobulin, calcitonin, TTF-1, CEA while primitive disease are usually positive ^{15,17,21,26}, remembering that only 20% to 30% of anaplastic carcinomas stain for thyroglobuline ^{19,43}. RCC metastases, on the other hand, are more frequently positive for CD10, vimentin, EMA, cytokeratin ^{11,14,21,23,25,44,46,47}. In our case, immunohistochemical results and clinical history of the patient led to the final diagnosis.

Prognosis of this condition usually depends on several factors, such as isolated metastases with absence of multiple organ disease; possibility of complete excision of the metastatic focus; histological characteristics of the primitive tumour; slow growth with absence of symptoms; long time interval between tumour resection and development of the metastases; extensive necrosis in the resected piece ^{6,15,16,26,48,49}. Overall prognosis is usually poor, since 35% to 80% of patients present multiple organ dissemination at the diagnosis of thyroid involvement 5,6,48, but local control of the disease could offer good survival rates, and surgical treatment is supported either way ^{50,51}: with curative intent, if primitive tumour has been resected and there are no signs of metastases in other organs 52; with palliative intent, avoiding airways obstruction and respiratory distress, in aggressive cases with fast growth 16,19,48,53.

The aim of surgical approach is to excise metastases with adequate margins, and while in localized, unilateral diseases lobectomy or isthmectomy have been considered, in multifocal diseases total thyroidectomy is to prefer ⁶, even though some authors suggested that conservative surgery might be more frequently associated with positive margins 54-56. Despite that, since metastases are not sensitive to radioactive iodine, total thyroidectomy is not mandatory as long as adequate margins are achieved⁶. With aggressive operative approaches and total excision of the disease, median survival reaches approximately 5 years after the diagnosis ^{19,57-59}. Regional lymph node involvement is rare, and prophylactic neck dissection is not required 6,54,60-62, but regional lymphatic should be assessed preoperatively, since RCC has a tendency to invade towards internal jugular vein ^{6,54}. In patients who cannot be thyroidectomised, methods to prolong survival include medical therapy, immunotherapy (e.g., interferon-), multikinase inhibitors (sunitinib, sorafenib, axitinib, pazopanib), antivascular endothelial growth factor agents (bevacizumab), and mammalian target of rapamycin inhibitors (temsirolimus, everolimus)¹⁵.

Since the difficulties in diagnosis and the delay of presentation, long-term follow up of the head and neck region should be standardized for those patient with a history of RCC, and a metastasis should be suspected in cases of thyroid disease, even years after the presentation of the primitive tumour. To thorax and abdomen CT scans, toutinely performed, should be added head and neck scans, especially in high-risk cases. Anyway, after diagnosis of thyroid metastasis is made, surgical approach, if technically possible, is more advisable, since it improves both survival and quality of life of the patient.

Riassunto

Le metastasi tiroidee hanno una percentuale di incidenza molto bassa, le più frequenti sono quelle dovute al carcinoma renale. In questo lavoro presentiamo il caso di in un paziente di sesso maschile di 70 anni, sottoposto circa 10 anni prima a nefrectomia sinistra per carcinoma renale. Il paziente è giunto alla nostra osservazione con diagnosi preoperatoria di gozzo multinodulare associato a tiroidite autoimmunitaria ed a linfadenopatia laterocervicale destra. Il paziente è stato sottoposto a tiroidectomia totale ed asportazione chirurgica del linfonodo laterocervicale destro. L'esame istologico ha esitato nella diagnosi di metastasi da carcinoma renale interessanti sia uno dei noduli tiroidei che il linfonodo laterocervicale. In considerazione del ritardo di presentazione e delle difficoltà diagnostiche, è consigliabile nei pazienti affetti da carcinoma renale anche un accurato follow-up a lungo termine del distretto testa-collo.

References

1. Willis RA: *Metastatic tumours in the thyroid gland*. Am J Pathol, 1931; 7:187-208-3.

2. Calzolari F, Sartori PV, Talarico C, Parmeggiani D, Beretta E, Pezzullo L, Bovo G, Sperlongano P, Monacelli M, Lucchini R, Misso C, Gurrado A, D'Ajello M, Uggeri F, Puxeddu E, Nasi P, Testini M, Rosato L, Barbarisio A, Avenia N: *Surgical treatment of intrathyroid metastases: Preliminary results of a multicentric study.* Anticancer Res, 2008; 28:2885-888.

3. Yoon JH, Kim EK, Kwak JY, Moon HJ, Kim GR: Sonographic features and ultrasonography-guided fine-needle aspiration of metastases to the thyroid gland. Ultrasonography, 2014; 33:40-8.

4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L: 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016; 26:1-133.

5. Chung AY, Tran TB, Brumund KT, Weisman RA, Bouvet M: *Metastases to the thyroid: A review of the literature from the last decade.* Thyroid, 2012; 22:258-68.

6. Nixon IJ, Coca-Pelaz A, Kaleva AI, Triantafyllou A, Angelos P, Owen RP, Rinaldo A, Shaha AR, Silver CE, Ferlito A: *Metastasis to the Thyroid Gland: A Critical Review.* Ann Surg Oncol, 2017; 24: 1533-39.

7. Pickhardt PJ, Pickard RH: Sonography of delayed thyroid metastasis from renal cell carcinoma with jugular vein extension. AJR Am J Roentgenol. 2003; 181:272-74.

8. Hegerova L, Griebeler ML, Reynolds JP, Henry MR, Gharib H: Metastasis to the thyroid gland: report of a large series from the Mayo Clinic. Am J Clin Oncol. 2015; 38: 338-42.

9. Ménégaux F, Chigot P: *Thyroid metastases*. Ann Chir, 2001; 126:981-84.

10. Ramirez-Plaza CP, Dominguez-Lopez ME, Blanco-Reina F: *Thyroid metastasis as initial presentation of clear cell renal carcinoma*. Int J Surg Case Rep, 2015; 10:101-03.

11. Heffes CS, Wenig BM, Thompson LD: Metastatic renal cell carcinoma to the thyroid gland: A clinicopathologic study of 36 cases. Cancer, 2002; 95:1869-878.

12. Riaz K, Tunio MA, Alasiri M, Elbagir Mohammad AA, Fareed MM: *Renal cell carcinoma metastatic to thyroid gland, presenting like anaplastic carcinoma of thyroid.* Case Rep Urol, 2013; 651081, http://dx.doi.org/10.1155/2013/651081.

13. Mohammadi A, Toomatari SBM, Ghasemi-Rad M: *Metastasis from renal cell carcinoma to thyroid presenting as rapidly growing neck mass.* Int J Surg Case Rep, 2014; 5:1110-112.

14. Demir L, Erten C, Somali I, Can A, Dirican A, Bayoglu V, Kucukzeybek Y, Altinboga AA, Ermete M, Oztop RM, Tarhan MO: *Metastases of renal cell carcinoma to the larynx and thyroid: Two case reports on metastasis developing years after nephrectomy.* Can Urol Assoc J, 2012; 6:E209-12.

15. Sindoni A, Rizzo M, Tuccari G, Ieni A, Barresi V, Calbo L, Cucinotta E, Trimarchi F, Benvenga S: *Thyroid Metastases from Renal Cell Carcinoma: Review of the Literature*. Scientific World Journal, 2010; 10; 590-602.

16. May M, Marusch F, Kaufmann O, Seehafer M, Helke C, Hoschke B, Gastinger I: Solitary renal cell carcinoma metastasis to

the thyroid gland. A paradigm of metastasectomy? Chirurg, 2003; 74: 768-74.

17. Foppiani L, Massolo M, Del Monte P, Bandelloni R, Arlandini A, Piccardo A: *Late-onset metastasis of renal cell carcinoma into a hot thyroid nodule: An uncommon finding not to be overlooked.* Case Rep Endocrinol. 2015; 268714,4 doi.org/10.1155/2015/268714.

18. Mathiesen JS, Fleischer JG, Godballe C: Renal cell carcinoma metastasis to the thyroid gland 15 years after nephrectomy. Ugeskr Laeger, 2015; 177:50-1.

19. Di Furia M, Della Penna A, Salvatorelli A, Clementi M, Guadagni S: *A single thyroid nodule revealing early metastases from clear cell renal carcinoma: Case report and review of literature.* Int J Surg Case Rep, 2017; 34:96-9.

20. Kihara XM, Yokomise H, Yamauchi A: *Metastasis of renal cell carcinoma to the thyroid gland 19 years after nephrectomy: A case report.* Auris Nasus Larynx, 2004; 31:95-100.

21. Medas F, Calò PG, Lai ML, Tuveri M, Pisano G, Nicolosi A: *Renal cell carcinoma metastasis to thyroid tumour: A case report and review of the literature.* J Med Case Rep, 2013; 7:265 doi: 10.1186/1752-1947-7-265.

22. Cilengir AH, Kalayci TO, Duygulu G, Rezanko TA, nci MF: *Metastasis of renal clear cell carcinoma to thyroid gland mimicking adenomatous goitre.* Pol J Radiol, 2016; 81:618-21.

23. Rizzo M, Rossi RT, Bonaffini O, Scisca C, Sindoni A, Altavilla G, Benvenga S: *Thyroid metastasis of clear cell renal carcinoma: Report of a case.* Diagn. Cytopathol, 2009; 37:759-62.

24. Papi G, Fadda G, Corsello SM, Corrado S, Rossi ED, Radighieri E, Miraglia A, Carani C, Pontecorvi A: *Metastases to the thyroid gland: Prevalence, clinicopathological aspects and prognosis: A 10-year experience.* Clin Endocrinol (Oxf), 2007; 66:565-71.

25. Shimaoka K: Thyrotoxicosis due to metastatic involvement of the thyroid. Arch Intern Med, 1980; 140:284-85.

26. Macedo-Alves D, Koch P, Soares V, Gouveia P, Honavar M, Taveira-Gomes A: *Thyroid metastasis from renal cell carcinoma: A case report after 9 years.* Int J Surg Case Rep, 2015; 16:59-63.

27. Surov A, Machens A, Holzhausen HJ, Spielmann RP, Dralle H: *Radiological features of metastases to the thyroid*. Acta Radiol, 2016; 57:444-50.

28. Nakhjavani MK, Gharib H, Goellner JR, van Heerden JA: *Metastasis to the thyroid gland. A report of 43 cases.* Cancer, 1997; 79:574-78.

29. Pang PYK, Koh AJH, Tan NC, Agrawal R: A case of late metastasis of a renal cell carcinoma to a multinodular goitre. Ann Acad Med Singapore, 2011; 40:298-99.

30. Kim TY, Kim WB, Gong G, Hong SJ, Shong YK: *Metastasis to the thyroid diagnosed by fine-needle aspiration biopsy.* Clin Endocrinol (Oxf), 2005; 62:236-41.

31. Duggal NM, Horattas MC: Metastatic renal cell carcinoma to the thyroid gland. Endocr Pract, 2008; 14:1040-46.

32. Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations. Cancer, 2007; 111:306-15.

33. Kobayashi K, Hirokawa M, Yabuta T, Fukushima M, Masuoka H, Higashiyama T, Kyhara M. Ito Y., Miya A, Amino M, Miyauchi

A: Metastatic carcinoma to the thyroid gland from renal cell carcinoma: role of ultrasonography in preoperative diagnosis. Thyroid Res, 2015; 8:4.

34. Choi SH, Baek JH, Ha EJ, Choi YJ, Song DE, Kim JK, Chung KW, Kim TY, Lee JH: *Diagnosis of metastasis to the thyroid gland: comparison of core-needle biopsy and fine-needle aspiration*. Otolaryngol Head Neck Surg, 2016; 154:618-25.

35. Di Stasi V, D'Antonio A, Caleo A, Valvano L: *Metastatic renal* cell carcinoma to the thyroid gland 24 years after the primary tumour. BMJ Case, 2013; bcr2012007569. doi: 10.1136/bcr-2012-007569.

36. Jallu A, Latoo M, Pampori R: *Rare case of renal cell carcinoma with mandibular swelling as primary presentation*. Case Rep Urol, 2013; doi: 10.1155/2013/806192.

37. Miah MS, White SJ, Oommen G, Birney E, Majumdar S: *Late simultaneous metastasis of renal cell carcinoma to the submandibular and thyroid glands seven years after radical nephrectomy.* Int J Otolaryngol, 2010; doi: 10.1155/2010/698014.

38. Song OK, Koo JS, Kwak JY, Moon HJ, Yoon JH, Kim EK: *Metastatic renal cell carcinoma in the thyroid gland: Ultrasonographic features and the diagnostic role of core needle biopsy.* Ultrasonography, 2017; 36: 252-59.

39. Moon WJ, Baek JH, Choi JW, Kim YJ, Ha EJ, Lim HK, Song DE, Lee JH, Shong JK: *The value of gross visual assessment of specimen adequacy for liquid-based cytology 2during ultrasound-guided, ne-needle aspiration of thyroid nodules.* Endocr Pract, 2015; 1:1219-226. 92-109.

40. Truong LD, Shen SS: Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med, 2011; 135:92-109.

41. Nixon IJ, Whitcher M, Glick J, Palmer FL, Shaha AL, Shah JP, Patel SG, Ganly I: *Surgical management of metastases to the thyroid gland*. Ann Surg Oncol, 2011; 18:800-04.

42. El Fakih RO, Delgado FA, Harstine LR: Marked thyroid enlargement secondary to renal cell carcinoma metastasis with acute respiratory failure. Thyroid, 2009; 19:917-8 doi: 10.1089/thy.2008.0399.

43. Hurlimann J, Gardiol D, Scazziga B: *Immunohistology of anaplastic thyroid carcinoma. A study of 43 cases.* Histopathology 1987; 11:567-80.

44. Lee JG, Yang Y, Kim KS, Hyun CL, Lee JS, Koh G, Lee D: *A case of metastatic renal cell carcinoma to thyroid gland*. Chonnam Med J, 2011; 47:130-33.

45. Carcangiu ML, Sibley RK, Rosai: *Clear cell change in primary thyroid tumors. A study of 38 cases.* Am J Surg Pathol, 1985; 9: 705-22.

46. Green LK, Ro JY, Mackay B, Ayala AG, Luna MA: Renal cell carcinoma metastatic to the thyroid. Cancer, 1989; 63:1810-825.

47. Linton RR, Barney JD, Moorman HD, Lerman J: *Metastatic hypernephroma of the thyroid gland*. Surg Gynecol Obstet, 1946; 83: 493-98.

48. Iesalnieks I, Winter H, Bareck E, et al.: *Thyroid metastases of renal cell carcinoma: Clinical course in 45 patients undergoing surgery. Assessment of factors affecting patients' survival.* Thyroid, 2008; 18: 615-24.

49. Kierney PC, van Heerden JA, Segura JW, Weaver AL: Surgeon's role in the management of solitary renal cell carcinoma metastases occur-

ring subsequent to initial curative nephrectomy: An institutional review. Ann Surg Oncol, 1994; 1:345-52.

50. Thelen A, Jonas S, Benckert C, Lopez-Hanninen E, Rudolph B, Neuman U, Neuhaus P: *Liver resection for metastases from renal cell carcinoma*. World J Surg, 2007; 31:802-07.

51. Ljungberg B, Bensalah K, Canfield S, et al.: *EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol.* 2015; 67:913-24.

52. Quaglino F, Beccaris M, Iacopini S, Mazzara E, Suriani A, Palladin D, Valli M: *Solitary thyroid metastasis of clear cell renal carcinoma: case report.* Tumori 2009; 95:367-70.

53. Romero Arenas MA, Ryu H, Lee S, Morris LF, Grubbs EG, Lee JE, Perrier ND: *The role of thyroidectomy in metastatic disease to the thyroid gland.* Ann Surg Onco, 2014; 21:434-49.

54. Ishikawa M, Hirano S, Tsuji T, Ito J: Management of metastasis to the thyroid gland. Auris Nasus Larynx, 2011; 38:426-30.

55. Seki H, Ueda T, Shibata Y, Sato Y, Yagihashi N: Solitary thyroid metastasis of renal clear cell carcinoma: Report of a case. Surg Today, 2001; 31:225-29.

56. Benoit L, Favoulet P, Arnould L, Margarot A, Franceschini C, Collin F., et al.: *Metastatic renal cell carcinoma of the thyroid gland: about seven cases and review of the literature.* Ann Chir, 2003; 129: 218-23.

57. Beutner U, Leowardi C, Bork U, Lüthi C, Tarantino I, Pahernik S, Wente MN, Büchler MW, Schmied BM, Müller SA: *Survival after renal cell carcinoma metastasis to the thyroid: Single center experience and systematic review of the literature.* Thyroid, 2015; 25: 314-24.

58. Wood K, Vini L, Harmer C: Metastases to the thyroid gland: The Royal Marsden experience. Eur J Surg Oncol, 2004; 30:583-88.

59. Solmaz A, Muhammedoglu A, Altnay S, Erçetin C, Yavuz E, Gülçiçek OB, Yalcin S, Erbil Y: *Isolated thyroid metastasis from renal cell carcinoma*. Turk J Surg, 2017; 33:110-12.

60. Burt A, Goudie RB: *Diagnosis of primary thyroid carcinoma by immunohistological demonstration of thyroglobulin*. Histopathology, 1979; 3:279-86.

61. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: A case report and review of the literature. Ear Nose Throat J, 2009; 88: E7.

62. Kumamoto K, Utsumi Y, Sugano K, Hoshino M, Suzuki S, Takenoshita S: Colon carcinoma metastasis to the thyroid gland: Report of a case with a review of the literature. Tumori, 2006; 92: 252-56.